Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2017
At a glance
- Drugs LY 2795050 (Primary)
- Indications Post-traumatic stress disorders
- Focus Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 30 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 30 Mar 2016 Status changed from active, no longer recruiting to discontinued as the principal investigator Dr. Alex Neumeister left NYU in March 2015 as reported by ClinicalTrials.gov.